Suppr超能文献

钙拮抗剂之间的药理差异。

Pharmacological differences between calcium antagonists.

作者信息

Opie L H

机构信息

Ischaemic Heart Disease Research Unit, Medical Research Council, University of Cape Town Medical School, South Africa.

出版信息

Eur Heart J. 1997 Jan;18 Suppl A:A71-9. doi: 10.1093/eurheartj/18.suppl_a.71.

Abstract

The calcium channel antagonists are not an homogeneous group. From both pharmacological and clinical points of view, they can be divided into those of the dihydropyridine family like nifedipine, and those of the non-dihydropyridine family like verapamil and diltiazem. These families bind at different sites to the calcium channel, which may explain some of the clinical differences. The dihydropyridines are more vascular selective and the non-dihydropyridines are more myocardial selective and tend to reduce the heart rate. Further important differences are between short- and long-acting forms of the calcium channel antagonists. From the clinical point of view, these agents are most used in angina pectoris and hypertension. Emerging studies suggest that in angina of effort these agents have a safety record somewhat similar to that of beta-blockers. In congestive heart failure, these agents, as a group, are contraindicated.

摘要

钙通道拮抗剂并非一类同质的药物。从药理学和临床角度来看,它们可分为二氢吡啶类,如硝苯地平,以及非二氢吡啶类,如维拉帕米和地尔硫䓬。这些类别在钙通道的不同位点结合,这可能解释了一些临床差异。二氢吡啶类药物对血管的选择性更高,而非二氢吡啶类药物对心肌的选择性更高,且往往会降低心率。钙通道拮抗剂的短效和长效剂型之间也存在进一步的重要差异。从临床角度来看,这些药物最常用于治疗心绞痛和高血压。新出现的研究表明,在劳力性心绞痛中,这些药物的安全性记录与β受体阻滞剂有些相似。在充血性心力衰竭中,作为一个整体,这些药物是禁忌的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验